Neurotoxin compositions for use in treating cardiovascular disorders
AssigneeAeon Biopharma, Inc.
InventorsGregory F. Brooks, Adelbert L. Stagg
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods for use in treating cardiovascular disorders.
Claims30
1)-38) (canceled)
39) A method of treating a cardiovascular disorder comprising:
- administering a botulinum toxin into the stellate ganglion nerve of a mammal or the vicinity thereof to treat at least one of angina, arrhythmias of heart rate, a myocardial contractility disorder, coronary artery disease, and high blood pressure;
- thereby reducing the occurrence of at least one symptom of the disorder.
42) A method of treating a cardiovascular disorder comprising;
- administering a botulinum toxin into the stellate ganglion or the vicinity thereof in a subject with a cardiovascular disorder to thereby treat their symptoms.
43) A method of treating a cardiovascular disorder comprising administering a botulinum toxin into the stellate ganglion or the vicinity thereof wherein the administration is performed by imaging the treatment area.
52) A method for comparing the efficacy and safety of two different Botulinum toxins, comprising:
- measuring a reduction of a cardiovascular disorder symptom of an individual resulting from administration of a first botulinum neurotoxin;
- measuring a reduction of a cardio disorder symptom of an individual resulting from administration of a second botulinum neurotoxin;
- and comparing the reduction in symptoms to determine a difference between the first botulinum neurotoxin and the second botulinum neurotoxin.
53) A method of treating a cardiovascular disorder comprising the steps of administering a botulinum toxin into the stellate ganglion nerve of a mammal or into the vicinity thereof to treat at least one of arrhythmias of heart rate, a myocardial contractility disorder, coronary artery disease, and high blood pressure;
- and administering a local anesthetic to the stellate ganglion nerve of said mammal, thereby reducing the occurrence of at least one symptom of the disorder.
56) The method of claim 1, wherein said administration comprises locating the cricoid cartilage of the larynx to identify the location of the stellate ganglion and injecting into the stellate ganglion or vicinity thereof.
Dependencies are inferred from the claim text.